BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 109 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,940,805 | +1.8% | 415,368 | +1.2% | 0.00% | 0.0% |
Q2 2023 | $2,888,991 | -13.9% | 410,368 | +2.0% | 0.00% | 0.0% |
Q1 2023 | $3,355,749 | -34.9% | 402,368 | -10.4% | 0.00% | -50.0% |
Q4 2022 | $5,154,153 | -7.1% | 448,968 | +2.0% | 0.00% | 0.0% |
Q3 2022 | $5,546,000 | +20.5% | 440,168 | +1.2% | 0.00% | +33.3% |
Q2 2022 | $4,602,000 | -33.5% | 434,968 | +2.2% | 0.00% | -25.0% |
Q1 2022 | $6,918,000 | +27.2% | 425,468 | +8.4% | 0.00% | +33.3% |
Q4 2021 | $5,437,000 | -3.6% | 392,568 | 0.0% | 0.00% | -25.0% |
Q3 2021 | $5,641,000 | -8.5% | 392,568 | +0.7% | 0.00% | 0.0% |
Q2 2021 | $6,164,000 | +50.2% | 389,868 | -3.4% | 0.00% | +33.3% |
Q1 2021 | $4,103,000 | +38.0% | 403,468 | +1.1% | 0.00% | +50.0% |
Q4 2020 | $2,974,000 | +120.8% | 399,168 | +1.8% | 0.00% | +100.0% |
Q3 2020 | $1,347,000 | -26.7% | 392,268 | +1.7% | 0.00% | -50.0% |
Q2 2020 | $1,838,000 | +207.4% | 385,668 | +29.1% | 0.00% | +100.0% |
Q1 2020 | $598,000 | -39.0% | 298,800 | +5.2% | 0.00% | 0.0% |
Q4 2019 | $980,000 | +144.4% | 284,000 | +103.0% | 0.00% | – |
Q3 2019 | $401,000 | -24.3% | 139,900 | 0.0% | 0.00% | -100.0% |
Q2 2019 | $530,000 | -53.5% | 139,900 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $1,139,000 | +4.2% | 139,900 | +3.3% | 0.00% | 0.0% |
Q4 2018 | $1,093,000 | +19.3% | 135,400 | +12.8% | 0.00% | 0.0% |
Q3 2018 | $916,000 | +33.1% | 120,000 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $688,000 | -15.8% | 120,000 | -29.9% | 0.00% | 0.0% |
Q1 2018 | $817,000 | -2.9% | 171,300 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $841,000 | -6.3% | 171,300 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $898,000 | +41.2% | 171,300 | +49.9% | 0.00% | 0.0% |
Q2 2017 | $636,000 | -33.8% | 114,300 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $960,000 | +57.4% | 114,300 | +18.7% | 0.00% | 0.0% |
Q4 2016 | $610,000 | +43.5% | 96,300 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $425,000 | +55.7% | 96,300 | 0.0% | 0.00% | – |
Q2 2016 | $273,000 | +3.8% | 96,300 | 0.0% | 0.00% | – |
Q1 2016 | $263,000 | -67.5% | 96,300 | +22.8% | 0.00% | -100.0% |
Q4 2015 | $809,000 | -9.5% | 78,400 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $894,000 | -12.2% | 78,400 | +15.0% | 0.00% | -33.3% |
Q2 2015 | $1,018,000 | +69.9% | 68,200 | +2.9% | 0.00% | +50.0% |
Q1 2015 | $599,000 | -25.7% | 66,300 | 0.0% | 0.00% | -33.3% |
Q4 2014 | $806,000 | +29.0% | 66,300 | +3.8% | 0.00% | +50.0% |
Q3 2014 | $625,000 | -34.5% | 63,900 | -14.6% | 0.00% | -50.0% |
Q2 2014 | $954,000 | +63.4% | 74,800 | +35.5% | 0.00% | +100.0% |
Q1 2014 | $584,000 | +75.4% | 55,200 | +26.0% | 0.00% | +100.0% |
Q4 2013 | $333,000 | – | 43,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |